Shockwave C2+ Catheter Expands Utility of IVL in Calcified Coronary Arteries Shockwave C2+ is commercially available for the treatment of de novo coronary artery disease in Europe and select other ...
Johnson & Johnson has put forward a clinical study exploring the use of its Shockwave Medical division’s vessel-clearing approach as the primary procedure for women with hardened, calcified blockages ...
Shockwave Medical Inc. enrolled the first patient in its EMPOWER CAD study, the first prospective, all-female study of percutaneous coronary intervention (PCI). The study seeks to confirm the benefits ...
EMPOWER CAD, a global prospective, multi-center, real-world study, reaffirms favorable acute outcomes for coronary IVL in female patients, unlike other calcium modification tools PARIS, May 20, 2025 ...
Shockwave Medical, a unit of New Brunswick, N.J.-based Johnson & Johnson Medtech, completed enrollment in the first prospective all-female study of percutaneous coronary intervention in complex ...
SANTA CLARA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results